<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03434314</url>
  </required_header>
  <id_info>
    <org_study_id>1.0</org_study_id>
    <secondary_id>733203</secondary_id>
    <secondary_id>ET 127/2-1</secondary_id>
    <nct_id>NCT03434314</nct_id>
  </id_info>
  <brief_title>Paraplegia Prevention in Aortic Aneurysm Repair by Thoracoabdominal Staging</brief_title>
  <acronym>PAPA-ARTiS</acronym>
  <official_title>Paraplegia Prevention in Aortic Aneurysm Repair by Thoracoabdominal Staging With 'Minimally-Invasive Segmental Artery Coil-Embolization': A Randomized Controlled Multicentre Trial - PAPA-ARTiS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad de Granada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Clinical Research Infrastructure Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Modus Research and Innovation Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Society of Cardiology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aortic aneurysms represent the most common and dangerous aortic diseases. Although
      conventional aortic repair techniques cure the disease, there is a high risk of paraplegia
      particularly in extensive thoracoabdominal aneurysms due to impaired blood supply to the
      spinal cord.

      The PAPA-ARTiS trial will assess the clinical safety and efficacy of the MISACE
      (Minimally-Invasive Segmental Artery Coil-Embolization) procedure, a novel therapeutic
      concept to reduce the risk of paraplegia due to aneurysm repair.

      The study investigates the MISACE procedure as a potential pre-treatment prior to open or
      endovascular aneurysm repair in patients with thoracoabdominal aortic aneurysms. Patients
      will be randomized to one of the two treatment strategies: a) aneurysm repair without MISACE
      pre-treatment, or b) aneurysm repair with MISACE pre-treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic aortic aneurysms are permanent and localized dilations of the aorta that remain
      asymptomatic for long periods of time, but continue to increase in diameter before they
      eventually rupture. Left untreated, the patients' prognosis is dismal, since the internal
      bleeding of the rupture brings about sudden death. Although successful treatment cures the
      disease, the risky procedures compromise spinal cord blood supply acutely and permanently,
      frequently leading to paraplegia, particularly for aneurysms involving crucial segmental
      arteries, i.e. thoracoabdominal aortic aneurysms of Crawford type II &amp; III. Although various
      strategies have achieved a remarkable decrease in the incidence of paraplegia, it is still no
      less than 10-20%.

      However, it has recently been found that the deliberate staged occlusion of the segmental
      arteries to the paraspinous collateral network finally supplying the spinal cord can trigger
      arterial collateralization, thus stabilizing blood supply from alternate inflow sources and
      preventing ischaemia.

      This has been translated to a clinically available therapeutic option, 'minimally invasive
      staged segmental artery coil embolization' (MISACE), which proceeds in a 'staged' manner to
      occlude groups of arteries under highly controlled conditions, after which time must be
      allowed for arteriogenesis to build a robust collateral blood supply.

      PAPA-ARTiS is a multi-national, prospective, open-label, two-arm, randomized controlled trial
      to demonstrate, that a minimally invasive staged treatment approach can reduce paraplegia and
      mortality in patients undergoing thoracoabdominal aortic aneurysm (TAAA) repair.

      Patients with planned aneurysm repair will be included in the study and will be randomized
      1:1 in the control group or the MISACE-group. The control group receives treatment as per
      standard institutional protocol - open or endovascular repair without MISACE. In the
      MISACE-group, segmental arteries will be occluded in one to three sessions some weeks before
      the definite repair. Segmental arteries are occluded with coils or plugs.This induces
      arteriogenesis and the building of a robust collateral network ultimately supplying the
      spinal cord. During aneurysm repair, these new arteries provide an alternate blood supply to
      the spinal cord and thereby help prevent paraplegia.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is to greatly reduce incidence of ischaemic spinal cord injury and mortality.</measure>
    <time_frame>30 days after TAAA repair</time_frame>
    <description>Successful treatment of the aneurysm is a binary variable. All of the following criteria must be met for this composite endpoint to count as a success:
The patient is alive and without substantial spinal cord injury 30 days after treatment, and
the aneurysm did not rupture and has been excluded within six months of randomization. Substantial spinal cord injury will be determined with a modified Tarlov scale (see below).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>substantial spinal cord injury</measure>
    <time_frame>30 days after TAAA repair and at one year after TAAA repair</time_frame>
    <description>Substantial spinal cord injury is defined as zero to two on the modified Tarlov scale.
0. No lower extremity movement
Lower extremity motion without gravity
Lower extremity motion against gravity
Able to stand with assistance
Able to walk with assistance
Normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>spinal cord injury according to the modified Tarlov scale from TAAA repair to one year</measure>
    <time_frame>from date of TAAA repair and up to one year after TAAA repair</time_frame>
    <description>Spinal cord injury will be determined with a modified Tarlov scale (see above).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>at 30 days and one year after TAAA repair</time_frame>
    <description>all-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stay in intensive care unit and intermediate care</measure>
    <time_frame>from date of TAAA repair and up to one year after TAAA repair</time_frame>
    <description>length of stay in intensive care unit and intermediate care unit after TAAA repair</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sub-group analyses</measure>
    <time_frame>up to one year after TAAA repair</time_frame>
    <description>sub-group analyses of spinal cord injury according to modified Tarlov scale (see above) for open repair and endovascular repair separately</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sub-group analyses</measure>
    <time_frame>up to one year after TAAA repair</time_frame>
    <description>sub-group analyses of mortality for open repair and endovascular repair separately</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>re-operation for bleeding</measure>
    <time_frame>from date of TAAA repair and up to one year after TAAA repair</time_frame>
    <description>re-operation for bleeding (only for open repair)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cross-clamping times</measure>
    <time_frame>during open surgery</time_frame>
    <description>cross-clamping times during open surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>residual aneurysm sac perfusion</measure>
    <time_frame>up to one year after TAAA repair</time_frame>
    <description>residual aneurysm sac perfusion, i.e. type II endoleaks (only for endovascular repair)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>costs</measure>
    <time_frame>up to one year after TAAA repair</time_frame>
    <description>incremental cost-effectiveness ratio (ICER) will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality Adjusted Life Years</measure>
    <time_frame>up to one year after TAAA repair</time_frame>
    <description>Quality Adjusted Life Years (QALYs) will be estimated over one year</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Aortic Aneurysm, Thoracoabdominal</condition>
  <arm_group>
    <arm_group_label>MISACE arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Minimally-Invasive Segmental Artery Coil-Embolization
MISACE procedure prior to aneurysm repair
segmental arteries are occluded with coils or plugs in one to three MISACE sessions (staged procedure)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>receives treatment of aneurysm as usual: open surgical repair or endovascular repair without MISACE</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Minimally-Invasive Segmental Artery Coil-Embolization</intervention_name>
    <description>During one single MISACE session 3-7 segmental arteries will be occluded. The procedure is conducted through a peripheral artery access in local anaesthesia. Microcoils or vascular plugs will be used for the occlusion itself.</description>
    <arm_group_label>MISACE arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  TAAA, Crawford type II or III

          -  planned open or endovascular repair of aneurysm within four months

          -  ≥ 18 years old

        Exclusion Criteria:

          -  complicated (sub-) acute type B aortic dissection

          -  ruptured and urgent aneurysm (emergencies)

          -  untreated aortic arch aneurysm

          -  bilaterally occluded iliac arteries or chronic total occlusion of left subclavian
             artery

          -  pre-operative neurological deficits or spinal cord dysfunction

          -  major untreated cardio-pulmonary disease

          -  life-expectancy of less than one year

          -  high risk for segmental artery embolism

          -  severe contrast agent allergy, severe reduction in glomerular filtration rate (CKD
             stage 4)

          -  expected lack of compliance

          -  pregnant or nursing women

          -  impaired thyroid function, if not under stable treatment

          -  women of child bearing potential without highly effective contraceptive measures

          -  current participation in other interventional clinical trial

          -  patients under legal supervision or guardianship

          -  patients placed in an institution by official or court order
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian D Etz, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Leipzig</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian D Etz, Prof. Dr.</last_name>
    <phone>+49 341 865 251007</phone>
    <email>christian.etz@medizin.uni-leipzig.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Petroff, Dr.</last_name>
    <phone>+49 341 97 16 354</phone>
    <email>david.petroff@zks.uni-leipzig.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Grimm, Prof. Dr.</last_name>
      <phone>+43 512 504 22500</phone>
      <email>michael.grimm@tirol-kliniken.at</email>
    </contact>
    <contact_backup>
      <last_name>Johannes Holfeld, Dr.</last_name>
      <email>johannes.holfeld@i-med.ac.at</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Hietzing</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Grabenwöger, Prof. Dr.</last_name>
      <phone>+43 1 4020585</phone>
      <email>Martin.Grabenwoeger@wienkav.at</email>
    </contact>
    <contact_backup>
      <last_name>Gabriel Weiss, Dr.</last_name>
      <email>gabriel.weiss@wienkav.at</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital of Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Ducasse, Prof. Dr.</last_name>
      <phone>+335 56 79 55 25</phone>
      <email>eric.ducasse@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marie Lannelongue Hospital</name>
      <address>
        <city>Le Plessis-Robinson</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephan Haulon, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Jacobs, Prof. Dr.</last_name>
      <phone>+49 241 8085197</phone>
      <email>mjacobs@ukaachen.de</email>
    </contact>
    <contact_backup>
      <last_name>Drosos Kotelis, Dr.</last_name>
      <email>dkotelis@ukaachen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Volkmar Falk, Prof. Dr.</last_name>
      <email>falk@dhzb.de</email>
    </contact>
    <contact_backup>
      <last_name>Semih Buz, Dr.</last_name>
      <email>buz@dhzb.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hubert Schelzig, Prof. Dr.</last_name>
      <phone>0049 211 81 07211</phone>
      <email>hubert.schelzig@med.uni-duesseldorf.de</email>
    </contact>
    <contact_backup>
      <last_name>Alexander Oberhuber, Dr.</last_name>
      <email>Alexander.Oberhuber@med.uni-duesseldorf.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Westdeutsches Herz und Gefäßzentrum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heinz Jakob, Prof. Dr.</last_name>
      <phone>+49 201 723 4901</phone>
      <email>heinz.jakob@uk-essen.de</email>
    </contact>
    <contact_backup>
      <last_name>Konstantinos Tsagakis, Dr.</last_name>
      <email>Konstantinos.Tsagakis@uk-essen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg/ Bad Krozingen</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Czerny, Prof. Dr.</last_name>
      <phone>+49 7633 402 6216</phone>
      <email>martin.czerny@universitaets-herzzentrum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tilo Kölbel, Prof. Dr.</last_name>
      <phone>+49 40 7410 58609</phone>
      <email>t.koelbel@uke.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hanover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Axel Haverich, Prof. Dr.</last_name>
      <phone>0049 511- 532 6580</phone>
      <email>haverich.axel@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Malakh Shrestha, Prof. Dr.</last_name>
      <phone>0049 511- 532 6238</phone>
      <email>Shrestha.Malakh.lal@mh-hannover.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dittmar Böckler, Prof. Dr.</last_name>
      <phone>0049 6221 56 6249</phone>
      <email>dittmar.boeckler@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Moritz Bischoff, Dr.</last_name>
      <email>moritz.bischoff@med.uni-heidelberg.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian D Etz, Prof. Dr.</last_name>
      <phone>+49 341 865 251007</phone>
      <email>christian.etz@medizin.uni-leipzig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UniversitätskIinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Scheinert Dierk, Prof.Dr.</last_name>
      <phone>+49 341 97 18770</phone>
      <email>dierk.scheinert@medizin.uni-leipzig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar (TU München)</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans-Henning Eckstein, Prof. Dr.</last_name>
      <phone>+49 89 4140 9244</phone>
      <email>H.H.Eckstein@lrz.tum.de</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Geisbüsch, Dr.</last_name>
      <email>sarah.geisbuesch@mri.tum.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München (LMU)</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maximilian Luehr, Dr.</last_name>
      <phone>+ 49 89 4400 72436</phone>
      <email>maximilian.luehr@med.uni-muenchen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Franziskus-Hospital GmbH</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Torsello, Prof. Dr.</last_name>
      <phone>0049 251 935-3933</phone>
      <email>giovanni.torsello@ukmuenster.de</email>
    </contact>
    <contact_backup>
      <last_name>Theodosios Bisdas, Dr.</last_name>
      <email>theodosios.bisdas@sfh-muenster.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Paracelsus Universität - Klinikum Nürnberg</name>
      <address>
        <city>Nuremberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Verhoeven, Prof. Dr.</last_name>
      <phone>0049 911 398 117004</phone>
      <email>eric.verhoeven@klinikum-nuernberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Athanasios Katsargyris, Dr.</last_name>
      <email>Athanasios.Katsargyris@klinikum-nuernberg.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karin Pfister, Prof. Dr.</last_name>
      <phone>+49 941 944 6911</phone>
      <email>Karin.Pfister@klinik.uni-regensburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Piotr Kasprzak, Prof. Dr.</last_name>
      <email>piotr.kasprzak@ukr.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Schlensak, Prof. Dr.</last_name>
      <phone>0049 7071 29 86638</phone>
      <email>christian.schlensak@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Mario Lescan, Dr.</last_name>
      <email>mario.lescan@med.uni-tuebingen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>S.Orsola-Malpighi Hospital</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Davide Pacini, Prof. Dr.</last_name>
      <phone>+39 051 6363329</phone>
      <email>davide.pacini@unibo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele SRL</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Chiesa, Prof. Dr.</last_name>
      <phone>+39 02 2643 7148</phone>
      <email>chiesa.roberto@unisr.it</email>
    </contact>
    <contact_backup>
      <last_name>Germano Melissano, Prof. Dr.</last_name>
      <phone>+39 02 2643 7148</phone>
      <email>melissano.germano@hsr.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Jacobs, Prof. Dr.</last_name>
      <email>m.jacobs@mumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Barend Mees, Dr.</last_name>
      <phone>+31 43 3877478</phone>
      <email>barend.mees@mumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medical University of Warsaw</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tomasz Jakimowicz, Dr.</last_name>
      <email>tomj@wum.edu.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Silesian Center for Heart Diseases</name>
      <address>
        <city>Zabrze</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marian Zembala, Prof. Dr.</last_name>
      <phone>+48 323733689</phone>
      <email>m.zembala@sccs.pl; sek.kch@sccs.pl</email>
    </contact>
    <contact_backup>
      <last_name>Maciej K Kolowca, Dr.</last_name>
      <email>maciej@kolowca.eu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital Malmoe</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tim Resch, Dr.</last_name>
      <email>tim.resch@med.lu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Larzon, Prof. Dr.</last_name>
      <email>thomas.larzon@regionorebrolan.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jürg Schmidli, Prof. Dr.</last_name>
      <phone>+41 31 632 26 02</phone>
      <email>juerg.schmidli@insel.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Bartholomews Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aung Y Oo, Prof. Dr.</last_name>
      <email>AungYe.OO@Bartshealth.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2018</study_first_submitted>
  <study_first_submitted_qc>February 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2018</study_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Christian Etz</investigator_full_name>
    <investigator_title>Prof. Dr. Christian Etz</investigator_title>
  </responsible_party>
  <keyword>Paraplegia</keyword>
  <keyword>Aortic Aneurysm Repair</keyword>
  <keyword>Staging</keyword>
  <keyword>Embolization</keyword>
  <keyword>TAAA</keyword>
  <keyword>Thoracoabdominal aortic aneurysm</keyword>
  <keyword>MISACE</keyword>
  <keyword>Spinal cord ischemia</keyword>
  <keyword>Spinal cord ischaemia</keyword>
  <keyword>Spinal cord injury</keyword>
  <keyword>Spinal cord ischemic injury</keyword>
  <keyword>Spinal cord ischaemic injury</keyword>
  <keyword>Permanent paraplegia</keyword>
  <keyword>Temporary paraplegia</keyword>
  <keyword>Paraparesis</keyword>
  <keyword>SCI</keyword>
  <keyword>TAAA repair</keyword>
  <keyword>Open TAAA repair</keyword>
  <keyword>Open surgical TAAA repair</keyword>
  <keyword>Endovascular TAAA repair</keyword>
  <keyword>TEVAR</keyword>
  <keyword>Aortic surgery</keyword>
  <keyword>Thoracoabdominal aortic surgery</keyword>
  <keyword>Type B aortic dissection</keyword>
  <keyword>Chronic type B aortic dissection</keyword>
  <keyword>Stanford type B aortic dissection</keyword>
  <keyword>Collateral network</keyword>
  <keyword>Paraspinal collateral network</keyword>
  <keyword>Paraspinous collateral network</keyword>
  <keyword>Arteriogenesis</keyword>
  <keyword>Intercostal arteries</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Paraplegia</mesh_term>
    <mesh_term>Aortic Aneurysm, Thoracic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

